Carbonic anhydrase 13 suppresses bone metastasis in breast cancer.
Animals
Biomarkers, Tumor
/ analysis
Bone Neoplasms
/ genetics
Breast Neoplasms
/ genetics
Carbonic Anhydrases
/ analysis
Cell Line, Tumor
Cell Movement
/ genetics
Disease-Free Survival
Female
Gene Expression Regulation, Neoplastic
Humans
Macrophage Colony-Stimulating Factor
/ genetics
Mice
Neoplasm Invasiveness
/ genetics
Neoplasm Recurrence, Local
/ epidemiology
Prognosis
Survival Rate
Vascular Endothelial Growth Factor A
/ genetics
Xenograft Model Antitumor Assays
Bone metastasis
Breast cancer
CA13
Invasion
Migration
Journal
Cancer treatment and research communications
ISSN: 2468-2942
Titre abrégé: Cancer Treat Res Commun
Pays: England
ID NLM: 101694651
Informations de publication
Date de publication:
2021
2021
Historique:
received:
22
12
2020
revised:
02
02
2021
accepted:
05
02
2021
pubmed:
16
2
2021
medline:
4
1
2022
entrez:
15
2
2021
Statut:
ppublish
Résumé
Metastatic progression is the leading cause of mortality in breast cancer. However, molecular mechanisms that govern this process remain unclear. In this study, we found that carbonic anhydrase 13 (CA13) plays a potential role in suppressing bone metastasis. iRFP713-labeled iCSCL-10A (iRFP-iCSCL-10A) breast cancer cells, which exhibit the hallmarks of cancer stem cells, exerted the ability of bone metastasis in hind legs after 5-week injections, whereas no metastasis was observed in control iRFP713-labeled MCF-10A (iRFP-MCF10A) cells. Transcriptome analysis indicated that the expression of several genes, including metabolism-related CA13, was reduced in bone metastatic iRFP-iCSCL-10A cells. In vitro and in vivo analyses demonstrated that overexpression of CA13 in iRFP-iCSCL-10A cells suppressed migration, invasion, and bone metastasis, together with the reduction of VEGF-A and M-CSF expression. Furthermore, we found that breast cancer patients with a low CA13 expression had significantly shorter overall survival and disease-free survival rates compared to those with higher CA13 expression. These findings suggest that CA13 may act as a novel prognostic biomarker and would be a therapeutic candidate for the prevention of bone metastasis in breast cancer.
Identifiants
pubmed: 33588197
pii: S2468-2942(21)00031-9
doi: 10.1016/j.ctarc.2021.100332
pii:
doi:
Substances chimiques
Biomarkers, Tumor
0
CSF1 protein, human
0
VEGFA protein, human
0
Vascular Endothelial Growth Factor A
0
Macrophage Colony-Stimulating Factor
81627-83-0
CA13 protein, human
EC 4.2.1.1
Carbonic Anhydrases
EC 4.2.1.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
100332Informations de copyright
Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.